{"disease":{"id":"myasthenia-gravis-ocular","name":"myasthenia gravis ocular"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06617741","title":"Myasthenia Gravis Foundation of America Global MG Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3800,"lead_sponsor_name":"Myasthenia Gravis Foundation of America","has_results":false},{"nct_id":"NCT05380128","title":"Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese Population","phase":"","overall_status":"COMPLETED","enrollment_count":297,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT07249632","title":"A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT03049956","title":"OVEMP in Myasthenia","phase":"NA","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT05214612","title":"Predictors and Prognostic Factors of Myasthenia Gravis Outcome","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05045248","title":"Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"American University of Beirut Medical Center","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}